Pharmacotherapy of Psoriasis Support With Antiphospholipid Syndrome: Abc/Ven Analysis of Anti-Viral Drugs

The aim was to research the pharmacotherapy of psoriasis with antiphospholipid syndrome based on ABC/VEN analysis of antiviral drugs. The materials of the study were the clinical and pharmacological groups for pharmacotherapy of psoriasis on the background of antiphospholipid syndrome. Regulatory, documentary, marketing, pharmacoeconomic, ABC/VEN research methods were used. Studied the clinical and pharmacological groups of the most drugs INN for basic pharmacotherapy of psoriasis have diagnostic codes of ATC classification L "Antineoplastic and immunomodulatory agents" and code M "Agents affecting the musculoskeletal system". In the article, the results of share of different medical forms of drugs for pharmacotherapy of psoriasis with antiphospholipid syndrome were shown. Matrix of the consolidated ABC-VEN analysis of drugs for pharmacotherapy of psoriasis with antiphospholipid syndrome was developed during the research. Shown the relevance and necessity of the chosen research topic because of a review of the scientific literature on epidemiology and pharmacotherapy. Marketing research of medicines were determined by assortment, country of origin, dosage forms, and registration certificates. Estimated that in the A/E categories, drugs coincide and are in a niche with an affordable share (17.04%). In terms of priority for pharmacotherapy of psoriasis on the background of antiphospholipid syndrome, a matrix of the combined ABC/VEN analysis was developed. The results of the study provide an opportunity to make administrative and managerial decisions in determining the pharmacotherapy of psoriasis with antiphospholipid syndrome to improve the use pharmaceutical provision for patients with systemic autoimmune diseases.